


REMARKS

In response to the restriction requirement, Applicants provisionally elect with traverse the invention set forth in Group II, claims 9-22, drawn to the compounds, compositions, and methods of use of the compounds of formula I where A-B is $\text{NR}^5\text{-SO}_2$ and where W is $(\text{CH}_2)_2$ or CH=CH .

Regarding the election of a single species, Applicants elect the compound of example 33:

6-Ethyl-*N*-{(1*S*,2*R*)-2-hydroxy-1-(phenylmethyl)-3-[(3,3,3-trifluoropropyl)amino]propyl}-1-methyl-1,3,4,6-tetrahydro[1,2]thiazepino[5,4,3-*cd*]indole-8-carboxamide 2,2-dioxide


depicted as:



This compound is encompassed by claims 9-18 and 20-22.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 25 July 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988